Hypera (OTCMKTS:HYPMY) Announces Earnings Results

Hypera (OTCMKTS:HYPMY) announced its earnings results on Thursday. The company reported $0.02 EPS for the quarter, Zacks reports. The firm had revenue of $258.56 million for the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%.

Hypera Stock Up 4.7 %

Shares of OTCMKTS:HYPMY opened at $3.62 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68. The stock’s 50-day moving average is $3.27 and its 200-day moving average is $3.74. Hypera has a 52-week low of $2.64 and a 52-week high of $6.90.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.